<unk> , sold under the brand name Tecartus, is a cell-based gene therapy medication for the treatment of mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL). The most common side effects include serious infections, low blood cell counts and a weakened immune system. The most common side effects for the treatment of ALL include fever, CRS, hypotension, encephalopathy, tachycardias, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, and vomiting.<unk>  is a chimeric antigen receptor T cell therapy and is the first cell-based gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of mantle cell lymphoma.<unk>  was approved for medical use in the United States in July 2020, and in the European Union in December 2020.
Brexucabtagene autoleucel
Ciltacabtagene autoleucel
Lisocabtagene maraleucel
Belantamab mafodotin
Idecabtagene vicleucel
Levomilnacipran
Nicogel
Dotinurad